American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
TR
Transcode Therapeutics, Inc.
$5.3MMarket cap
-$34.7MNet income
12Employees
RNAZNASDAQ
2021IPO
About Transcode Therapeutics, Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- -$34.7M
- Total assets
- $162.4M
- Market cap
- $5.3M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 9, 2021
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Transcode Therapeutics, Inc..
Write a review
Explore
Browse all →
